Abstract: A process component includes a first connection, a second connection, and an adjusting element arranged in a hollow space fluidically connecting the first connection to the second connection and that can be brought into a first position and second position in an axial direction within the hollow space. The component includes a permanent magnet, a first electrical coil, and a second electrical coil arranged in succession in the axial direction to create a simple process component whose size can be effectively scaled. The magnet, adjusting element, and a yoke form a first closed magnetic circuit in the first position and a second closed magnetic circuit in the second position. The first and second coil respectively compensate for the first circuit and the second circuit. The hollow space and adjusting element are shaped such that the valve can be penetrated by a fluid flow formed between the first and second connections.

Abstract: The present invention relates to cultivated cucumber plants comprising a yield QTL on chromosome 2 and/or a yield QTL on chromosome 6 of their genome, and to methods for generating such plants, and their use.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The invention relates to a handheld welding tool with external air supply for welding thermoplastic synthetic material, with a preferably wand-shaped housing containing at least one hot air generating device, and with flexible supply lines for air and power supply that are combined in a supply line package. The supply lines of the supply line package are connected with rear connection elements on the housing, to the supply line for the air supply encasing the power supply line as a sheath. The invention proposes to connect the supply line package rotatably to a common rear non-rotatable connection piece of the housing. This makes it possible to rotate the handheld welding tool with little force in relation to the supply line package in order to facilitate the handling of the handheld welding tool.

Abstract: The present application relates to procedures for the determination of the activity of the protease which activates factor VII, also known as factor VII activating protease or FSAP. The application also relates to a method of detecting whether an individual has increased or lowered activity in the protease which activates factor VII compared to at least one standard sample, wherein the increased or lowered activity indicates an increased risk for disease or cardiovascular complications.

Abstract: This application describes methods of treatment involving a protease for activating the blood clotting factor VII, which (a) activates blood clotting factor VII, (b) is inhibited by the presence of aprotinin, (c) is increased in its activity by the presence of at least one of the following: calcium ions, heparin, or heparin related substances, and (d) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more bands in the molecular weight range from 50 to 75 kDa, and in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa, and a band, which corresponds to a proenzyme, in the molecular weight range from 60 to 65 kDa.

Abstract: Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.

Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.

Abstract: An arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.

Abstract: Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.

Abstract: A procedure for the determination of the activity of the protease which activates blood clotting factor VII from protein solutions is describes, in which the protein solution comprising the protease and/or its proenzyme is incubated with a solid phase to which an antibody which binds the protease and/or its proenzyme has been coupled beforehand, and after washing the solid phase, the protease and/or its proenzyme fixed thereto, are incubated with reagents which allow for the determination of their activity.

Abstract: The invention relates to a handheld welding tool with external air supply for welding thermoplastic synthetic material, with a preferably wand-shaped housing containing at least one hot air generating device, and with flexible supply lines for air and power supply that are combined in a supply line package. The supply lines of the supply line package are connected with rear connection elements on the housing, to the supply line for the air supply encasing the power supply line as a sheath. The invention proposes to connect the supply line package rotatably to a common rear non-rotatable connection piece of the housing. This makes it possible to rotate the handheld welding tool with little force in relation to the supply line package in order to facilitate the handling of the handheld welding tool.